Zacks: Brokerages Anticipate Insulet Co. (NASDAQ:PODD) Will Post Quarterly Sales of $197.63 Million

Wall Street brokerages expect Insulet Co. (NASDAQ:PODD) to announce sales of $197.63 million for the current fiscal quarter, Zacks reports. Seven analysts have issued estimates for Insulet’s earnings. The highest sales estimate is $198.61 million and the lowest is $197.00 million. Insulet posted sales of $164.91 million during the same quarter last year, which suggests a positive year over year growth rate of 19.8%. The company is scheduled to issue its next quarterly earnings results on Monday, February 24th.

On average, analysts expect that Insulet will report full-year sales of $726.66 million for the current financial year, with estimates ranging from $725.80 million to $728.21 million. For the next fiscal year, analysts forecast that the business will report sales of $856.62 million, with estimates ranging from $792.42 million to $885.60 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Insulet.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Tuesday, November 5th. The medical instruments supplier reported $0.01 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.03 by ($0.02). Insulet had a net margin of 2.38% and a return on equity of 9.46%. The company had revenue of $192.12 million during the quarter, compared to analysts’ expectations of $179.50 million. During the same quarter in the prior year, the business earned $0.03 EPS. The business’s revenue for the quarter was up 27.2% compared to the same quarter last year.

Several research firms recently commented on PODD. JPMorgan Chase & Co. upgraded shares of Insulet from a “neutral” rating to an “overweight” rating and raised their price target for the company from $120.00 to $155.00 in a report on Tuesday, August 6th. Morgan Stanley raised their price target on shares of Insulet from $135.00 to $148.00 and gave the company an “equal weight” rating in a report on Wednesday. Jefferies Financial Group raised their price target on shares of Insulet from $105.00 to $140.00 and gave the company a “buy” rating in a report on Tuesday, August 6th. Guggenheim lowered shares of Insulet from a “buy” rating to a “neutral” rating in a report on Thursday, October 3rd. They noted that the move was a valuation call. Finally, Leerink Swann restated an “outperform” rating and issued a $185.00 price target (up previously from $160.00) on shares of Insulet in a report on Tuesday, September 24th. Ten equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Insulet currently has a consensus rating of “Hold” and an average price target of $151.71.

NASDAQ:PODD traded up $4.59 during mid-day trading on Thursday, hitting $169.46. 1,241,100 shares of the company’s stock traded hands, compared to its average volume of 751,627. Insulet has a 1 year low of $70.80 and a 1 year high of $171.96. The firm’s 50 day simple moving average is $154.75 and its 200 day simple moving average is $130.77. The company has a debt-to-equity ratio of 2.43, a quick ratio of 3.91 and a current ratio of 4.72. The company has a market cap of $8.73 billion, a PE ratio of 3,389.20 and a beta of 0.96.

In related news, SVP Michael P. Spears sold 4,153 shares of Insulet stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $146.12, for a total value of $606,836.36. Following the completion of the sale, the senior vice president now owns 22,626 shares in the company, valued at $3,306,111.12. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Shacey Petrovic sold 689 shares of Insulet stock in a transaction on Friday, November 1st. The stock was sold at an average price of $145.69, for a total transaction of $100,380.41. Following the completion of the sale, the chief executive officer now owns 94,510 shares of the company’s stock, valued at approximately $13,769,161.90. The disclosure for this sale can be found here. Insiders have sold 5,491 shares of company stock worth $806,124 in the last quarter. Insiders own 3.50% of the company’s stock.

Large investors have recently modified their holdings of the stock. Janus Henderson Group PLC increased its stake in shares of Insulet by 4.9% in the second quarter. Janus Henderson Group PLC now owns 369,611 shares of the medical instruments supplier’s stock worth $44,124,000 after buying an additional 17,328 shares during the last quarter. Swiss National Bank increased its stake in shares of Insulet by 2.4% in the second quarter. Swiss National Bank now owns 110,300 shares of the medical instruments supplier’s stock worth $13,168,000 after buying an additional 2,600 shares during the last quarter. Jennison Associates LLC increased its stake in shares of Insulet by 53.6% in the second quarter. Jennison Associates LLC now owns 283,817 shares of the medical instruments supplier’s stock worth $33,882,000 after buying an additional 98,995 shares during the last quarter. Columbus Circle Investors increased its stake in shares of Insulet by 74.6% in the second quarter. Columbus Circle Investors now owns 165,863 shares of the medical instruments supplier’s stock worth $19,801,000 after buying an additional 70,860 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Insulet by 2.7% in the second quarter. Charles Schwab Investment Management Inc. now owns 365,617 shares of the medical instruments supplier’s stock worth $43,648,000 after buying an additional 9,446 shares during the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.

Further Reading: What causes a recession?

Get a free copy of the Zacks research report on Insulet (PODD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.